Famitinib: all 53 studies that test it

Page 1 of 1. Open to participants first (21), then studies with results posted, then the rest; newest registration first within each.

• Perioperative Retlirafusp Alfa(Anti-PD-L1/TGF-β Bifunctional Fusion Protein) Plus Famitinib and GEMOX-Based Hepatic Arterial Infusion Chemotherapy for Locally Advanced Intrahepatic Cholangiocarcinoma: A Multicenter, Single-Arm, Exploratory Phase II TrialRecruitingNCT07847710Phase 2
• Retlirafusp Alfa Combined With Famitinib, Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Unresectable Pancreatic CancerNot yet recruitingNCT07814859Phase 2
• Adebrelimab With Famitinib and Chemotherapy as Neoadjuvant Therapy for ESCCRecruitingNCT07796113Phase 2
• Camrelizumab With Famitinib for Patients With Rare Head and Neck MalignanciesRecruitingNCT07662681Phase 1/2
• Camrelizumab Combined With Famitinib Malate and Chemotherapy for Treatment of Recurrent/ Metastatic Cervical CancerNot yet recruitingNCT07627620Phase 2
• Neoadjuvant SHR-1701 Plus Famitinib With Response-guided Adjuvant Therapy in Resectable Mucosal MelanomaNot yet recruitingNCT07517653Phase 2
• Famitinib Combined With SHR-A1811, Versus SHR-A1811 for CDK4/6 Inhibitors-resistent Advanced HR+/HER2- Breast Cancer With SNF4 SubtypeNot yet recruitingNCT07382687Phase 3
• A Randomized, Open-label, Double-cohort Study of Fluzoparib Combined With Famitinib Malate or SHR-1701 for Neoadjuvant Therapy in Patients With Advanced Ovarian CancerNot yet recruitingNCT07355010Phase 2
• Cryoablation Combined With SHR-1701 Plus Famitinib in Patients With Advanced Intrahepatic Cholangiocarcinoma.Not yet recruitingNCT07147088Phase 2
• A Prospective, Randomized, Parallel Trial of Famitinib Malate at Different Doses Combined With Camrelizumab for the Treatment of Recurrent and Metastatic Cervical CancerNot yet recruitingNCT07143292Phase 2
• Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast CancerRecruitingNCT06649331Phase 2
• Adibelimab, Famitinib and Chemotherapy for Advanced NSCLC After PD-1 Inhibitor FailureNot yet recruitingNCT06336954Phase 2
• Safety and Efficacy of Adebrelimab Plus Irinotecan Liposome (II) With or Without Famitinib in ES-SCLC Pre-treated With ImmunotherapyNot yet recruitingNCT06332950Phase 1/2
• A Study of Adebrelimab Combined With Famitinib and Chemotherapy in the Treatment of ES-SCLC.Not yet recruitingNCT06306560Phase 2
• Famitinib in Combination With Adebrelimab for the Treatment of Advanced Thyroid CancerNot yet recruitingNCT06146985Phase 2
• A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)RecruitingNCT05999149Phase 3
• Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.RecruitingNCT05760378Phase 3
• FUSCC Refractory TNBC Platform Study (FUTURE2.0)RecruitingNCT05749588Phase 2
• SNF Platform Study of HR+/ HER2-advanced Breast CancerRecruitingNCT05594095Phase 2
• Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant TherapyRecruitingNCT05582499Phase 2
• A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung CancerRecruitingNCT05042375Phase 3
• Single Dose Study To Study The Absorption, Metabolism And Excretion Of FamitinibStatus unknownNCT05473468Phase 1
• A Trial of Camrelizumab for Injection in Combination With Famitinib Malate Capsule and Paclitaxel For Injection(Albumin Bound) in Advanced Solid Tumors of PatientsStatus unknownNCT05214976Phase 2
• Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast CancerTerminatedNCT05176080Phase 1/2
• A Study to Evaluate Camrelizumab Combined With Famitinib as Subsequent Therapy in Patients With Advanced NSCLCTerminatedNCT05106335Phase 3
• To Explore the Efficacy and Safety of Camrelizumab Combined With SHR1020 in the Treatment of Advanced MelanomaStatus unknownNCT05051865Phase 2
• Pharmacokinetics Study of Famitinib Malate Capsules in Healthy SubjectsCompletedNCT05046808Phase 1
• SHR-1701 in Combination With Famitinib in Patients With Recurrent/Metastatic Nasopharyngeal CarcinomaStatus unknownNCT05020925Phase 1/2
• A Phase II Trial of Camrelizumab Combined With Famitinib for Adjuvant Treatment of Stage II-IIIA NSCLC.Status unknownNCT05005468Phase 2
• Camrelizumab Plus Famitinib as Treatment in Patient With Advanced or Metastatic Pulmonary Sarcomatoid CarcinomaCompletedNCT04888429Phase 2
• Efficacy and Safety of SHR-1020 Combined With Albumin-bound Paclitaxel in the Second-line Treatment of Pancreatic CancerStatus unknownNCT04814485Phase 2
• A Study of SHR6390 Combined With Famitinib in the Treatment of HR + / HER2- Advanced Breast Cancer.Status unknownNCT04733417Phase 2
• A Study of SHR-1210± SHR-1020 Versus Chemotherapy in Patients With Recurrent or Metastatic Cervical CancerCompletedNCT04680988Phase 2
• A Study to Evaluate SHR-1210 in Combination With Famitinib Plus Chemotherapy in Subjects With NSCLC.TerminatedNCT04619433Phase 3
• A Drug-drug Interaction Trial to Evaluate the Pharmacokinetics Effect of Rifampicin on FamitinibCompletedNCT04494659Phase 1
• A Trial of Famitinib in Patients With Failure of First-Line Treatment For Intrahepatic CholangiocarcinomaWithdrawnNCT04479904Phase 2
• Efficacy and Safety of Famitinib Versus Sunitinib in the Treatment of Advanced Gastrointestinal Stromal Tumour Patients After Failure of ImatinibTerminatedNCT04409223Phase 3
• A Bioequivalence Study of Famitinib Malate on Healthy Chinese VolunteersCompletedNCT04400123Phase 1
• An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC.Active, not recruitingNCT04395989Phase 2
• Molecularly Targeted Umbrella Study in Luminal Advanced Breast CancerStatus unknownNCT04355858Phase 2
• Study to Evaluate the Efficacy and Safety of Camrelizumab and Famitinib in Patients With Advanced Solid TumorCompletedNCT04346381Phase 2
• Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological TumorsStatus unknownNCT03827837Phase 2
• SHR1020 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Squamous Non Small Cell Lung CancerTerminatedNCT02766140Phase 3
• Safety and Efficacy Study of Famitinib in Patients With Advanced Colorectal Adenocarcinoma（FACT）CompletedNCT02390947Phase 3
• A Study of Famitinib in Patients With Advanced Non-squamous and Non-Small Cell Lung Cancer (NSCLC)SuspendedNCT02356991Phase 2
• A Study of Famitinib in Patients With Gastrointestinal Stromal TumorStatus unknownNCT02336724Phase 2
• A Study of Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine TumorTerminatedNCT01994213Phase 2
• A Study of Famitinib in Patients With Advanced Metastatic Renal Cell CancerCompletedNCT01829841Phase 2
• A Study of Famitinib in Patients With Advanced Colorectal CancerCompletedNCT01762293Phase 2
• A Phase I Study of Famitinib Malate in Patients With Solid TumorCompletedNCT01762280Phase 1
• A Study of Famitinib Malate in HER2-negative Metastatic Breast CancerCompletedNCT01653574Phase 2
• Concurrent Chemoradiotherapy With Famitinib for Patients With Locally Advanced Nasopharyngeal CarcinomaCompletedNCT01462474Phase 1
• Famitinib in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma (NPC)CompletedNCT01392235Phase 2

← Famitinib overview